ANL 29.68 Increased By ▲ 1.38 (4.88%)
ASC 20.22 Decreased By ▼ -0.03 (-0.15%)
ASL 24.98 Decreased By ▼ -0.12 (-0.48%)
BOP 8.28 Increased By ▲ 0.03 (0.36%)
BYCO 10.31 Increased By ▲ 0.17 (1.68%)
FCCL 22.20 Increased By ▲ 0.28 (1.28%)
FFBL 26.70 Decreased By ▼ -0.05 (-0.19%)
FFL 20.25 Increased By ▲ 0.15 (0.75%)
FNEL 9.03 Increased By ▲ 0.09 (1.01%)
GGGL 27.40 Increased By ▲ 1.15 (4.38%)
GGL 45.63 Increased By ▲ 3.01 (7.06%)
HUMNL 7.28 Increased By ▲ 0.08 (1.11%)
JSCL 21.85 Increased By ▲ 0.45 (2.1%)
KAPCO 39.60 Increased By ▲ 0.41 (1.05%)
KEL 3.91 Increased By ▲ 0.05 (1.3%)
MDTL 3.64 Increased By ▲ 0.10 (2.82%)
MLCF 45.54 Increased By ▲ 1.54 (3.5%)
NETSOL 161.80 Increased By ▲ 3.29 (2.08%)
PACE 7.45 Increased By ▲ 0.25 (3.47%)
PAEL 33.30 Increased By ▲ 0.50 (1.52%)
PIBTL 11.15 Increased By ▲ 0.11 (1%)
POWER 9.20 Increased By ▲ 0.09 (0.99%)
PRL 23.90 Increased By ▲ 0.95 (4.14%)
PTC 12.12 Increased By ▲ 0.29 (2.45%)
SILK 1.79 Increased By ▲ 0.03 (1.7%)
SNGP 50.60 Increased By ▲ 1.10 (2.22%)
TELE 17.04 Increased By ▲ 1.24 (7.85%)
TRG 162.50 Increased By ▲ 4.30 (2.72%)
UNITY 40.80 Increased By ▲ 0.80 (2%)
WTL 3.67 Increased By ▲ 0.15 (4.26%)
BR100 5,189 Increased By ▲ 64.21 (1.25%)
BR30 26,249 Increased By ▲ 598.06 (2.33%)
KSE100 47,758 Increased By ▲ 305.07 (0.64%)
KSE30 19,110 Increased By ▲ 124.84 (0.66%)

Coronavirus
VERY HIGH Source: covid.gov.pk
Pakistan Deaths
23,529
6724hr
Pakistan Cases
1,043,277
3,58224hr
7.19% positivity
Sindh
387,261
Punjab
358,387
Balochistan
30,627
Islamabad
88,344
KPK
145,306
World

EU says J&J to miss vaccine supply target in second quarter

  • EMA said in a statement to Reuters that 17 million doses had been forbidden from being used in the bloc after that decision.
  • The EU has ordered a total of 200 million doses from J&J, of which 55 million were to be delivered by the end of June.
16 Jun 2021

BRUSSELS: Johnson & Johnson is expected to miss its COVID-19 vaccine supply target to the European Union for the second quarter after millions of doses were banned for use in Europe over safety concerns, an EU Commission spokesman said.

The setback could cause new delays in the bloc's vaccination drive, although the EU now relies mostly on the Pfizer-BioNTech shot to inoculate its population. More than half of adults in the EU have so far received at least one shot.

The European drugs regulator last week said J&J doses sent to Europe from an Emergent factory in the United States would not be used as a precaution after a case of contamination with substances used for AstraZeneca shots, which are also manufactured in that factory.

EMA said in a statement to Reuters that 17 million doses had been forbidden from being used in the bloc after that decision.

"Following the non-release of these batches, the company is not expected to be in a position to deliver 55 million doses by the end of this quarter," the EU commission spokesman said on Wednesday.

The EU has ordered a total of 200 million doses from J&J, of which 55 million were to be delivered by the end of June. The company has so far delivered around 12 million shots of its single-dose vaccine.

The spokesman declined to say how many doses J&J was now expected to deliver by the end of June.

"The member states and the Commission have voiced their strong concerns regarding this shortfall," he told a news conference, adding that the EU continued to work with the company "towards the delivery of the agreed doses overall in this and following quarters".

Despite the possible delays that this may cause, the spokesman said the EU remained on track to meet its target of immunizing 70% of its adult population this summer.

"Johnson & Johnson remains committed to supplying 200 million doses of its COVID-19 vaccine to the European Union, Norway and Iceland and will continue to update the European Commission and member states in a timely manner as we refine delivery timelines," a spokeswoman for J&J said in a statement.

EMA approval of Russia's Sputnik V vaccine, meanwhile, has been delayed because a June 10 deadline to submit data was missed, sources have told Reuters. The head of Russia's RDIF sovereign wealth fund said on Wednesday it expected the vaccine to be approved by the EU within two months.